Xeris (XERS) Ships One Millionth Gvoke Unit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Xeris Ships One Millionth Gvoke® Unit
July 31, 2023 7:00 AM EDTUpdated guidelines recognize the benefits of ready-to-use glucagon
Protecting all people with diabetes at risk of severe hypoglycemia remains the goal
CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients lives by developing and commercializing innovative products across a range of therapies, today announced that Xeris has shipped more than one million units of Gvoke® the companys ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children with diabetes ages 2... More
